




WHERE TECHNOLOGY COMES TO **LIFE**

Q1 2025



Forward Looking Statement

This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the "Company" or "Pluri"), to the extent such statements do not relate to historical or current facts. For example, the Company is using forward looking statements when it discusses the potential of its solutions and innovations, including the potential to drive individual and global well-being and drive sustainability, its technological platform capabilities, its ability to leverage its expertise and platforms to create a network of ventures and partnerships, the capabilities and advantages of such network of companies, its platform ability to develop cell-based solutions, its ability to drive innovation and collaborate successfully with its ventures, , the cell expansion technology use by Ever After Foods to produce mass scale and cost effective food products efficiently and sustainably while solving industry challenges, the ability to reimagine coffee without the ecological cost, its ability to create rapid de-risked ventures, the belief that Coffeesai will be a promising company within a single year and that ICL and Pluri each has unique strengths to achieve their partnership's POC.. Forward-looking statements are based on management's current expectations, estimates, projections, and assumptions about future events, and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions about the Company, which are difficult to predict, including projections of the Company's future financial results, its anticipated growth strategies, and anticipated trends in its business and in the market generally. Therefore, actual future results, performance and trends may differ materially from these forward-looking statements due to a variety of factors, including, without limitation: changes in technology and market requirements; the Company may encounter delays or obstacles in launching and/or successfully completing its proposed plans, including research and development; its products may not be approved by regulatory agencies, their technology may not be validated as they progress further and their methods may not be accepted; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real world settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of the Company or its joint ventures to differ materially from those contemplated in such forward-looking statements. The factors listed above are not exclusive, and further information is contained in the Company's Annual Report on Form 10-K and other reports on file with the U.S. Securities and Exchange Commission. All forward-looking statements speak only as of the date of this presentation. Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements.

This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Company. The information to be presented is not intended to replace the need to review the Company's formal filings with the U.S Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K and any subsequent filings, prior to making any investment in the Company's securities. In case of any inconsistencies between the information provided in this presentation and the Company's regulatory filings, the latter will prevail. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission and available on the SEC's website, www.sec.gov.

Pluri Venture Creation



Company


- Nasdaq (PLUR), TASE (PLUR.Ta)
- Cash & Deposits: ~\$22 million (as of December 31, 2024)
- Based In Israel With **Global Presence**, Including In The USA and Europe
- Rich IP Portfolio With **~250 Patents** Globally
- In-house **GMP Manufacturing Facility**
- **Two Decades Of Experience** In Cell Processing And Mass Scale Technology Development



Sectors

 Regenerative Medicine

 Cultivated Meat

 Contract Development and Manufacturing Organization

 Cell-Based Agriculture




Partners



From Single Cells To Sustainable Solutions

Pluri harnesses the power of cells, the building blocks of life, to deliver eco-friendly solutions that aim to enhance individual well-being and drive positive global change



Eight Billion Lives. **One Planet.** **Zero Time to Waste.**



Aging and Health



Climate Change



Food Security



Sustainability

**A growing, aging world urgently needs
scalable, sustainable solutions**

Pluri Technological Platform

Cell-based innovations, powered by validated technology

Innovative

- **Patented 3D cell expansion**
High-quality cells produced in large quantities
- **Versatile cell source and types**
Compatible with human, animal, and plant cells
- **Modular production system**
Reduces costs and minimizes ecological impact

Validated

- **Automated, scalable process**
Efficient and fully controlled
- **In-house GMP facility**
Ensures quality and compliance with standards
- **Consistent batch production**
Proven reliability from batch to batch




PluriMatrix™

Industrial Scale Production



Over Two Decades of Leadership with Cell-based Solutions

Pluri leverages its expertise and proprietary platform for cell-based solutions to create **a collaborative network of ventures and partnerships**



Immunotherapy

AgTech

Acute Radiation

Osteoarthritis

CDMO

Cultivated Coffee

Cultivated Meat

And beyond

Cultivated cacao

Cell-based Technology Platform



A collaborative network of companies

Knowhow and expertise

Validated technology and robust IP


Deep market understanding and strong partnerships

Infrastructure and corporate services

GMP facility with operations and QA resources

A Clear Path to Venture Creation

Pluri's technology-based platform aims to enable accelerated development and scalable production of cell-based solutions



A Clear Path to Venture Creation

Pluri's technology-based platform enables accelerated development and scalable production of cell-based solutions

Feasibility & de-risking

Model options

Ventures



Pluri currently retains majority share ownership in every venture it creates

Pluri Establishes a Collaborative Network of Ventures

As each venture thrives, Pluri and its entire network grow stronger, aiming to drive continuous innovation and shared success

**Shared
Facilities and
Know-how**



**Accumulating
Expertise**



**IP
Improvements**



**Shared
Network
of Partners**



Joint Ventures



Growing the Future of Food with Cultivated Meat

ever after
FOODS

Ever After Foods leverages Pluri's cell expansion technology to produce mass scale, cost-effective food products in an efficient and sustainable manner, aiming to solve the industry's scalability challenges



Environmental

- Less land and water are required
- Fewer greenhouse gases
- Less agriculture-related pollution



Ethical

- Adheres to ethical animal welfare standards



Consumer

- Natural flavor modification
- Safe modification for healthier food and raw materials

Ever After Foods Milestones

ever after
FOODS

Jan.
2022

Collaboration between
Pluri and Tnuva announced

 **pluri** CELL-BASED SOLUTIONS AT SCALE ~84.2% ownership

 **TNUVA** ~15.8% ownership

- Tnuva invested \$7.5 million according to a **\$40 million pre-money valuation**
- Pluri granted exclusive global royalty-bearing **license to use its IP and expertise**

Dec.
2022

Joint venture
reaches POC

Mar.
2023

Launch of a **scalable platform** for **cost effective production** of cultivated meat products

Jun.
2024

\$10 million investment round led by **leading global corporates**

- License extended to include cultivated fish
- **Post investment Pluri holds 69%**

Feb.
2025

Ever After Foods and **Bühler collaborate to scale cultivated meat production** and distribution



Company Creation

Reimagining Coffee Without Ecological Cost



Climate Change

Global coffee production will decrease by half in the next 30 years due to global warming



Land Shortage

Land suitable for growing coffee will reduce by up to 50% by 2050




Price Instability

U.S. coffee import prices have risen by over 65%. Prices changed from \$390 cents per kg to \$624 and back to \$419 cents per kg (2009-2023)



Carbon Footprint

126 B kg of CO2 emissions per year
140 liters of water required to produce a single cup of coffee



Sources: NIH, World Coffee Research, World Economic Forum, ICO, Mordor Intelligence, GlobeNewswire

A Consistent Methodology for Rapid, De-risked Venture Creation




Coffeesai demonstrates the potential creation of a promising company within a single year



The Coffeesai Solution uses 100% Real Coffee

 coffeesai



 coffeesai



Out Licensing

The background of the slide features a top-down view of several glass petri dishes. Each dish contains a bacterial culture, showing a dense, textured surface. The dishes are arranged in a somewhat circular pattern. A semi-transparent orange rectangular overlay covers the left portion of the image, providing a background for the text.

PLX-R18 for Acute Radiation Syndrome

ARS is caused by exposure to high amounts of ionizing radiation, such as in nuclear reactor accidents or warfare

Ongoing studies and collaborations

- Studies conducted and funded by U.S. government (NIH, DoD)
- \$4.2 Million contract signed with the US NIAID¹
- Collaboration agreement with Hemafund to enhance Ukraine's radiation emergency preparedness

FDA

- FDA cleared Investigational New Drug (IND) application for PLX-R18 for the treatment of ARS in case of nuclear events
- Received FDA Orphan Drug Designation



Survival Rate

Significant increase vs placebo ($p < 0.0001$)



Blood Lineages

Significant recovery of blood lineages ($p < 0.001$)



1. This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93023C00012

Pluri's Recent Achievements



Launch of Immunotherapy Platform

To develop Placental MAIT cells to treat solid tumors. Pluri also secured a new U.S. granted patent and a collaboration with BIRAD



Launch of cell-based coffee business

Coffeesai to introduce innovative product that will revolutionize the coffee industry – to establish a collaboration with external investor



US Government Strategic contract for \$4.2m

Continued research for the treatment of acute radiation syndrome (ARS)

Pluri signs collaboration agreement with Hemafund to enhance Ukraine's radiation emergency preparedness



Collaborations with global agriculture corps

Developing cutting-edge, multi-national agtech solutions



Launch of CDMO business

Growth in revenues based on recent contracts



€7.5 million Collaboration with Charite Berlin

PROTO: Phase I/II study for treatment of Knee Osteoarthritis with Pluri's PLX cells



Cultivated meat collaboration with global food giants

Ever After Foods secures \$10 million strategic investment round and enters collaboration with Bühler to scale cultivated meat production and distribution



Consolidated cash balance \$27m (as of September 30, 2024)

We halved our burn rate to approximately \$16m per year




\$10m strategic investment and expansion into cacao market

Pluri secures \$6.5m strategic investment and purchases over 70% of Kokomodo, a company specializing in cultivated cacao. Pluri then secures an additional \$3.5 investment from major shareholder

Science in Service of Humanity

Pluri is a global leader in cell technology, aiming to deliver cell-based solutions with a goal to improve global well-being and drive sustainability in multiple sectors



Our Collaborative Network of Partnerships

Regulatory



EUROPEAN MEDICINES AGENCY



Scientific Collaborations and Partnering



Funding



Our Team



Yaky Yanay
CEO & President



Liat Zalts
Chief Financial Officer



Lior Raviv
Chief Technology Officer



Dr. Michal Sheleg, PhD
VP Clinical Development



Nimrod Bar Zvi
Chief Commercial Officer



Dr. Arthur Machlenkin, PhD
Chief Scientific Officer



Efrat Livne-Hadass
Chief Wellbeing Officer



Orly Amiran
Chief Quality Officer



Efrat Kaduri
Chief Business Development
Officer - Pharma

THANK YOU.

Our cell-based innovations are aimed at transforming industries with a goal to create a more sustainable, healthier world. From the food we eat to the medicine we consume, we are building solutions that can potentially serve humanity, one breakthrough at a time.



For further info: investor.relations@pluri-biotech.com